11/15
09:08 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.
High
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.
11/14
02:21 am
mrsn
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/13
07:00 am
mrsn
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
High
Report
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
11/6
08:00 am
mrsn
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
High
Report
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
10/15
03:40 pm
mrsn
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc [Yahoo! Finance]
Low
Report
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc [Yahoo! Finance]
8/27
10:55 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.